Name changed from Medical Science Systems to Interleukin..... incorporated in DE but address is in Watham, MA.....CEO exercises 20K of his 30K OPTS. on 12/5 (at .50) then dumps them a few days ago.....over the past year, insiders have been selling, not buying.....so long as at least 40% of the shares of Series A Preferred Stock remains outstanding, the holders of Series A Preferred Stock have the right to elect four of the directors of the Company and the holders of common stock have the right to elect a fifth director (management 4, "common" folk 1.....great ratio unless your prepared to buy 61% of the Series "A", to have a "say").
I Think I Will Pass On This One (THANK GOD FOR REG. FD)!
Go ahead and pass on what will be a very gig stock. Series A owned by the $6 Billion marketing machine called Alticor. Thousands and thousands of sales people WW (they do close to $2 billion in China). Privately held Alticor has this one public play, as far as I know. They want to see their equity investment in this Company grow and grow and grow. ILI will be a home run!
Good points but I personally find the risk / reward ratio unfavorable at the present time. I would like to see management have a greater vested interest in their personal ILI stock ownership (given their very small holdings at the present time). I would consider becoming a shareholder if management stops selling, and starts buying.
I will be on the sidelines for now...will keep it on my radar with hopes that ILI stays around for the long haul.